ARAZLO Lotion Demonstrates Statistically Significant Superiority Over Placebo with Favorable Efficacy, Safety and Tolerability Profile
Post Hoc Analysis of the Two Phase 3 Studies Also Published in JDD
RALEIGH, N.C., Jan. 13, 2020 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the Journal of Drugs in Dermatology (JDD) published positive results from two large Phase 3, multicenter, double-blind, placebo-controlled clinical trials (Studies 1 and 2) demonstrating the efficacy, safety and tolerability of ARAZLO™ (tazarotene) Lotion, 0.045%, the first FDA approved tazarotene in lotion form for patients with moderate to severe acne.1 A post hoc analysis of male patients in the two Phase 3 studies was also published by JDD.2 The U.S. Food and Drug Administration (FDA) approved ARAZLO for the topical treatment of acne vulgaris in patients nine years of age and older in December 2019.
“When treating moderate to severe acne, I like to prescribe a tazarotene treatment due to the retinoid’s efficacy, but find patients often struggle with tolerability issues, such as dry, irritated skin,” said Emil A. Tanghetti, M.D., lead ARAZLO study investigator and founder, Center for Dermatology and Laser Surgery, Sacramento, Calif. “This newly published data sheds light on the utility of ARAZLO, a new treatment option that features the efficacy of tazarotene along with improved tolerability in a lotion vehicle, which is easily spreadable and aesthetically pleasing. I look forward to offering this treatment to my patients with acne in the coming months.”